PFEBy Calypso Research8 min read

Pfizer Inc. (PFE) Q4 2025 Earnings Analysis

Pfizer's Profits Take a Pill with $17.6B in Revenue

Key Takeaways

Pfizer Inc. (PFE) reported Q4 2025 earnings with revenue of $17.6B, representing a -1.2% year-over-year change. The stock moved -3.3% on earnings day.

The bull case: A differentiated, globally-scaled obesity and oncology portfolio, underpinned by Seagen assets, monthly GLP-1 and AI-enabled R&D productivity, drives a new multi-year growth cycle that more than offsets LOEs and supports a durable, growing dividend.

The bear case: Intensifying competition in obesity and oncology, execution and tolerability risks in the late-starting GLP-1 franchise, and mounting LOE and capital allocation pressures prevent Pfizer’s pipeline from delivering enough incremental value to justify current investment and dividend commitments.

Financial Highlights

  • Revenue: $17.6B (-1.2% YoY)
  • Gross Profit: $12.3B (70.0% margin, -3.0% YoY)
  • Operating Income: $3.7B (21.0% margin, -11.2% YoY)
  • Net Income: $-1.6B
  • TTM Revenue: $62.6B

Stock Performance

  • Earnings Day Move: -3.3%
  • Year-to-Date: +7.5%
  • 1-Year Return: +1.5%
  • vs. S&P 500 (since earnings): +2.9%
  • vs. Nasdaq (since earnings): +5.8%

View live PFE data, AI chat, and interactive debates on Calypso →

What Management Said

Here are the key debates and direct quotes from Pfizer Inc.'s Q4 2025 earnings call:

Differentiation, Tolerability, and Commercial Role of PF‑06939944 (3944) Monthly GLP‑1 in Obesity

Sentiment: Positive

"In VESPA three, 3944 displayed a well-tolerated and favorable safety profile that is consistent with what has been observed with weekly GLP-1 receptor agonists... with no more than one instance of severe nausea or vomiting in any dose group and no instances of severe diarrhea." — Chris Boshoff
"We think when you take that efficacy and then you combine it with a lower medication burden through a monthly dose, that's a value proposition that's gonna resonate with patients, with providers, with payers because persistency simplicity matter and it also gives us the opportunity to switch patients from weekly onto therapy." — Aamir Malik

Breadth and Ambition of Pfizer’s Obesity Franchise Beyond 3944 (Amylin Combo, GIPR Antagonist, Oral GLP‑1, Quarterly GLP‑1)

Sentiment: Positive

"This year, we plan to advance 20 plus obesity trials, including 10 phase three studies of 3944 that span chronic weight management, obesity-associated comorbidities, and opportunities to increase patient optionality and access... We are targeting the first of a series of potential approvals in 2028." — Chris Boshoff
"We are enthusiastic about phase two studies with our ultra-long-acting amylin analog... we believe has the potential for class-leading efficacy and combinability with 3944 in a monthly dosing format... We continue to advance our potentially first-in-class oral Gipper antagonist... and additional phase one studies... including an injectable ultra-long-acting GiPA agonist, a potential quarterly dose injectable GLP-1 receptor agonist, and oral candidates." — Chris Boshoff

Global Commercial Opportunity and Pricing/Access Dynamics in Obesity (Ex‑US, Out‑of‑Pocket, Switching)

Sentiment: Positive

"What's really interesting in this category is actually the size of the market ex-US projected to be $150 billion, and 40% of that is actually ex-US... we see that there is high willingness to pay out of pocket across all mature markets... and we see the price point being across $250 to $350. Which is higher than what we had expected." — Alexandre de Germay
"This is not only ours, of course, weekly to monthly, but also any other GLP-1s that are in the market... they want to move up... into a maintenance with only one injection rather than with four... our research shows that most would like... to switch mostly to a more convenient needle, which is once a month." — Albert Bourla

R&D Intensity, LOE Management, and Use of AI to Offset Cost Burden

Sentiment: Mixed

"As we look at our in-line portfolio of products, we always continue to look to see how we can max the value... Vive is just a good example of a non-strategic asset for us monetizing that in such a way that we can redeploy that capital at higher returns... we will continue to do that as we think about our product portfolio going forward." — Dave Denton
"Many people are asking us how is it possible that Pfizer Inc. was able to take so much cost out of its operations without affecting the top line?... We didn't just cut cost. What we did is we improved productivity. And the main lever... was the successful deployment of AI where basically... we are reducing the cost without that being seen in the activity." — Albert Bourla

Oncology Strategy and Seagen Integration (ADC Portfolio, SV/β6 ADC, PADCEV, PD‑1/VEGF Bispecific 4404)

Sentiment: Mixed

"Overall, the Seagen portfolio is progressing ahead of our expectations... we accelerate a number of other programs into phase three including SV with two phase three studies ongoing... PD-L1B and another phase three program ongoing in non-small cell lung cancer and a number of phase one ADCs that's differentiated, including using the integrin beta-six antigen as a marker." — Chris Boshoff
"We are confident in the two studies. I agree with you that the second-line study against docetaxel, none of the other ADCs have really shown a benefit over docetaxel, but everything we've seen so far gives us confidence in the trial... events are slower than we expected, so that could mean either [our drug] performing better." — Chris Boshoff

Bull Case

A differentiated, globally-scaled obesity and oncology portfolio, underpinned by Seagen assets, monthly GLP-1 and AI-enabled R&D productivity, drives a new multi-year growth cycle that more than offsets LOEs and supports a durable, growing dividend.

Bear Case

Intensifying competition in obesity and oncology, execution and tolerability risks in the late-starting GLP-1 franchise, and mounting LOE and capital allocation pressures prevent Pfizer’s pipeline from delivering enough incremental value to justify current investment and dividend commitments.

Looking Ahead

With revenue declining -1.2% year-over-year, investors will be watching for signs of a turnaround at Pfizer Inc., particularly around differentiation, Tolerability, and Commercial Role of PF‑06939944 (3944) Monthly GLP‑1 in Obesity. With operating margins at 21.0%, margin trends will remain a focal point. The market's negative earnings-day reaction signals that investors need to see stronger execution, and the next earnings report will be a key catalyst for the stock.

Frequently Asked Questions

What was Pfizer Inc.'s revenue in Q4 2025?

Pfizer Inc. reported Q4 2025 revenue of $17.6B, representing a -1.2% year-over-year change.

Did Pfizer Inc. beat earnings expectations in Q4 2025?

The stock declined -3.3% on earnings day, suggesting the results fell short of market expectations. The current bull case centers on: A differentiated, globally-scaled obesity and oncology portfolio, underpinned by Seagen assets, monthly GLP-1 and AI-enabled R&D productivity, drives a new multi-year growth cycle that more than offsets LOEs and supports a durable, growing dividend.

What is the bull case for PFE stock?

The bull case for PFE centers on: A differentiated, globally-scaled obesity and oncology portfolio, underpinned by Seagen assets, monthly GLP-1 and AI-enabled R&D productivity, drives a new multi-year growth cycle that more than offsets LOEs and supports a durable, growing dividend.

What is the bear case for PFE stock?

The bear case for PFE centers on: Intensifying competition in obesity and oncology, execution and tolerability risks in the late-starting GLP-1 franchise, and mounting LOE and capital allocation pressures prevent Pfizer’s pipeline from delivering enough incremental value to justify current investment and dividend commitments.

How has PFE stock performed since its Q4 2025 earnings?

PFE moved -3.3% on the day of its Q4 2025 earnings report, outperforming the S&P 500 by +2.9% since earnings. Year-to-date, the stock has returned +7.5%.

Browse all 400+ earnings reports →

Learn More

Analyze PFE in Real Time

This is a static snapshot. For live financial data, AI-powered chat, and interactive earnings debates for Pfizer Inc. and 400+ other stocks, explore the full platform.

Open PFE on Calypso →

Calypso is an AI-powered equity research platform used by investment teams to cut earnings research time by over 80%.